Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Blueberry Therapeutics Ltd.. (5/5/16). "Press Release: Blueberry Therapeutics Raises £3m to Progress the Development of Its Lead Topical Antifungal".

Organisations Organisation Blueberry Therapeutics Ltd.
  Organisation 2 GM&C Life Sciences Fund
  Group Catapult Ventures (Group)
Products Product BB2603 (terbinafine-nano) (Blueberry Therapeutics)
  Product 2 venture capital
Index term Index term Blueberry Therapeutics–SEVERAL: investment, 201605 financing round £3m led by GM&C Life Sciences Fund managed by Catapult Ventures

Blueberry Therapeutics today announced that it has raised £3 million to progress the development of its topical fungal infection therapies into human clinical trials. The investment was led by the GM&C Life Sciences Fund, managed by Catapult Ventures, and included participation from San Francisco-based InClin Investments, as well as a number of private investors.

The investment will support progress of its innovative treatment for onychomycosis (fungal nail infection) and associated tinea pedis (athlete’s foot), into clinical development. In this large existing market valued at more than $3bn annually, patients have wanted a topical treatment for onychomycosis that has the effectiveness of existing oral treatment but without the toxicity concerns.

Record changed: 2018-08-21


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Blueberry Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top